Charles L Shapiro
Overview
Explore the profile of Charles L Shapiro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
159
Citations
6102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roy A, Jiang C, Perimbeti S, Deng L, Shapiro C, Gandhi S
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686540
Background: The interaction between HER2-low expression, oncotype recurrence score (RS), and their influence on the prognosis of HR+/HER2- breast cancer (BC) is not very well studied. Methods: We conducted a...
2.
Jiang C, Yabroff K, Deng L, Wang Q, Perimbeti S, Shapiro C, et al.
J Natl Cancer Inst
. 2023 May;
115(7):815-821.
PMID: 37185777
Background: Lack of safe, reliable, and affordable transportation is a barrier to medical care, but little is known about its association with clinical outcomes. Methods: We identified 28 640 adults...
3.
Power S, Bickel K, Chen R, Chiang A, Garrett-Mayer L, Makhoul I, et al.
JCO Oncol Pract
. 2023 Jan;
19(4):e520-e526.
PMID: 36669136
Purpose: Despite the growing calls for early and ubiquitous completion of advance directives (ADs), studies exploring links between AD completion and their impact on outcomes of patients with cancer have...
4.
Jiang C, Perimbeti S, Deng L, Shapiro C, Gandhi S
NPJ Breast Cancer
. 2022 Dec;
8(1):135.
PMID: 36585415
The development of novel anti-HER2 drugs opens new treatment options for women with breast cancers, including lower expression of HER2. The epidemiology and clinical outcome of metastatic HER2-low breast cancer...
5.
Jiang C, Yabroff K, Deng L, Wang Q, Perimbeti S, Shapiro C, et al.
JAMA Oncol
. 2022 Mar;
8(5):775-778.
PMID: 35323841
No abstract available.
6.
Jiang C, Deng L, Karr M, Wen Y, Wang Q, Perimbeti S, et al.
Cancer
. 2021 Oct;
128(4):828-838.
PMID: 34706057
Background: Cancer survivors develop other chronic medical conditions because of shared risk factors and delayed effects of cancer treatment. This study investigated trends in the prevalence of chronic diseases and...
7.
Shapiro C, Zubizarreta N, Moshier E, Brockway J, Mandeli J, Markham M, et al.
JCO Oncol Pract
. 2021 Jul;
17(8):e1170-e1180.
PMID: 34283637
Purpose: The ASCO Quality Oncology Practice Initiative (QOPI) project was established to evaluate the influence of guideline recommendations on routine clinical practice. Methods: QOPI provided summary data from 839 unique...
8.
Shapiro C
Clin Breast Cancer
. 2021 May;
21(5):e618-e630.
PMID: 34045175
Bone-modifying agents (BMAs) are mainstays in breast cancer and prevent and treat osteoporosis in early-stage disease and reduce skeletal metastases complications in advanced disease. There is some evidence to support...
9.
Collier K, Valencia H, Newton H, Hade E, Sborov D, Cavaliere R, et al.
Cancer Chemother Pharmacol
. 2021 Jan;
87(5):599-611.
PMID: 33492438
Purpose: Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the safety and tolerability of...
10.
Shapiro C
Cancers (Basel)
. 2020 Oct;
12(11).
PMID: 33114141
Osteoporosis is both a long-term effect (occurs during treatment and extends after treatment) and a late-effect (occurs after treatment ends) of breast cancer treatments. The worldwide prevalence of osteoporosis is...